News

benzinga_article
2026.05.06 14:40
InflaRx shares are trading higher after the company announced that it intends to develop izicopan, an oral C5a receptor inhibitor with potential best-in-class properties, in AAV, a life-threatening kidney disorder.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer